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Introduction: A systematic review and meta-analysis were performed to determine the diagnostic 
performance of dynamic contrast enhanced computed tomography (DCE-CT) for the differentiation 
between malignant and benign pulmonary nodules. 
 
Methods: Ovid MEDLINE and EMBASE were searched for studies published up to October 2018 on 
the diagnostic accuracy of DCE-CT for the characterization of pulmonary nodules. For the index test, 
studies with a minimum of a pre- and post-contrast computed tomography scan were evaluated. 
Studies with a reference standard of biopsy for malignancy, and biopsy or 2-year follow-up for 
benign disease were included.  Study bias was assessed using QUADAS-2 (Quality Assessment of 
Diagnostic Accuracy Studies). The sensitivities, specificities, and diagnostic odds ratios were 
determined along with 95% confidence intervals (CIs) using a bivariate random effects model.   
 
Results: Twenty-three studies were included, including 2397 study participants with 2514 nodules 
with 55.3% malignancy (1389/2514).  The pooled accuracy results were: sensitivity 94.8% (95%CI 
91.5;96.9), specificity 75.5% (69.4;80.6), diagnostic odds ratio 56.6 (24.2-88.9). QUADAS 2 
assessment showed intermediate/high risk of bias in a large proportion of the studies (52-78% 
across the domains).  No difference was present in sensitivity or specificity between subgroups when 
studies were split based on CT technique, sample size, nodule size, or publication date.  
 
Conclusion: DCE-CT has a high diagnostic accuracy for the diagnosis of pulmonary nodules although 
study quality was indeterminate in a large number of cases.   
 
Other:  
The meta-analysis was prospectively registered on PROSPERO (CRD42018112215).  The trial was 
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Key points 
• The pooled accuracy results were sensitivity 95.1% and specificity 73.8% although individual 
studies showed wide ranges of values. 
• This is comparable to the results of previous meta-analyses of PET/CT (Positron emission 
tomography/computed tomography) diagnostic accuracy for the diagnosis of solitary 
pulmonary nodules. 
• Robust direct comparative accuracy and cost effectiveness studies are warranted to 
determine the optimal use of DCE-CT and PET/CT in the diagnosis of SPNs.  
 
Abbreviations 
DCE-CT: Dynamic contrast enhanced computed tomography 
PET:  Positron emission tomography 
SPN:   Solitary pulmonary nodules 
SROC:   Summary receiver operator characteristic 
PLR:  Positive likelihood ratio  
NLR:  Negative likelihood ratio  
DOR:   Diagnostic odds ratio 
HU:   Hounsfield units 
QUADAS:  Quality Assessment of Diagnostic Accuracy Studies   
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INTRODUCTION   
Despite significant advances in the diagnosis and treatment of lung cancer, it remains the leading 
cause of cancer mortality [1]. Although only a proportion of patients with lung cancer present with a 
solitary pulmonary nodule (SPN) on diagnostic imaging tests, this is an important group as an SPN 
can represent early stage lung cancer, with higher survival rates following surgical resection than 
larger lesions [2]. However, not all SPNs turn out to be lung cancer and the accurate characterisation 
of SPNs is an ongoing diagnostic challenge with significant associated health costs [3]. With the 
adoption of low dose Computed Tomography (CT)-based lung cancer screening programmes in many 
countries, the number of patients with a SPN requiring further investigation is likely to increase 
substantially [4].  
 
An SPN is defined as a single pulmonary lesion less than 30mm in size [5]. Positron emission 
tomography with computed tomography (PET/CT) is currently the recommended test for the 
investigation of an indeterminate SPN ≥8mm, particularly when a biopsy is not possible [6, 7]. 
However PET/CT is only available in specialist centres, with more limited availability than CT, which 
can make access more difficult for an older population with a high burden of co-morbidities [8, 9].  In 
addition, PET/CT is both time consuming and expensive relative to other non-invasive imaging 
modalities such as CT. Where PET/CT measures the metabolism within the tissue of interest, 
dynamic contrast enhanced CT (DCE-CT) allows measurement of the vascularity of the tissue [10].  
The degree of enhancement on DCE-CT has been shown to correlate well with grade of lung cancer 
and the vessel density in the tumour [11, 12].  DCE-CT can be performed on most modern CT 
machines in current use and is therefore potentially readily accessible to patients.  Furthermore 
DCE-CT could potentially be performed at the same CT examination at which the pulmonary nodule 
is found.  Early work suggested a high diagnostic accuracy for DCE-CT, however this previous analysis 
incorporated a relatively small number of studies [13]. 
 
The aim of this systematic review of the literature and meta-analysis was to determine the 
diagnostic performance of dynamic contrast enhanced computed tomography (DCE-CT) for the 





MATERIALS AND METHODS   
The study was prospectively enrolled in PROSPERO (CRD42018112215).  The study has been 
reported in accordance with the Preferred Reporting Items for a Systematic Review and Meta-
analysis of Diagnostic Test Accuracy Studies (PRISMA-DTA) statement [14].  
The population of interest were those with a solitary pulmonary nodule undergoing a dynamic 
contrast enhanced CT as part of a work-up to determine the malignant or benign status of the 
nodule. The inclusion criteria were studies examining solitary pulmonary nodules being worked up 
for malignancy, and excluded those which included participants <18 years old, and those with pure 
ground glass nodules.  The intervention of interest was dynamic contrast enhanced computed 
tomography. Computed tomographic scans were included as long as there was a minimum of both a 
pre-contrast and post contrast enhanced CT dataset for the quantification of the degree of 
enhancement.  The gold standard against which the test was examined was required to be 
histological diagnosis of malignancy obtained from either needle biopsy or surgical resection, with 
benign status confirmed either histologically or with follow-up imaging showing no growth at 2 years 
or resolution.  We considered both prospective and retrospective diagnostic accuracy studies which 
contained sufficient data to construct contingency tables in order to assess true positive, false 
positive, true negative and false negative results.   
To identify articles of interest for review, Ovid MEDLINE and EMBASE were searched for published 
studies from their inception until October 2018 on the diagnostic accuracy of DCE-CT in the 
characterization of pulmonary nodules.  The full search strategy is documented in Supplementary 
Table S1.  Titles and abstracts of studies retrieved using the search strategy and those from 
additional sources were all independently screened by two reviewers (J.W.M and S.J, both with 1 
year experience) to identify studies that potentially met the inclusion criteria outlined above. The 
full text of these potentially eligible studies were retrieved and independently reviewed by the two 
reviewers to assess for eligibility.  Where there was a disagreement between the reviewers, a 
consensus was reached through discussion. The references of the retrieved full text articles were 
screened for further articles of interest and if any articles were found these were retrieved if they 
had not been previously identified with the original search strategy. 
A single reviewer (J.W-M) used a standardised, pre-piloted form to extract data from the included 
studies for assessment of study quality and evidence synthesis. Extracted information included study 
population and participant demographics and baseline characteristics; details of the CT scanning 
hardware, scanning technique, and diagnostic threshold used; study methodology; nodule size range 
and eventual diagnosis; diagnostic accuracy metrics; radiation dose. 
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Two review authors (J.W-M and S.J) independently assessed the risk of bias in the included studies 
through the use of the second version of the Quality Assessment of Diagnostic Accuracy Studies 
(QUADAS-2) questionnaire [15]. Discordance in the scoring of bias between the two reviewers were 
resolved by a third review author (L-M.D). 
Three deviations occurred from the original pre-registered protocol.  A size threshold was not pre-
specified in the original protocol, yet upon the literature review it became apparent that the upper 
size limit included varied markedly between studies. Although the Fleischner and BTS guidelines 
state that the upper limit of an SPN is 30mm, we allowed up to 40mm for the purpose of this 
analysis due to the high quality of many of the studies using this threshold, and the granularity it 
would provide the review.  However, an analysis was performed to compare studies with and 
without nodules above 30mm as described in the statistical section.  While our original protocol 
called for the analysis of solitary pulmonary nodules, we found that although several studies 
recruited cases based on the detection of a solitary pulmonary nodule, if an additional nodule was 
detected at the time of the index test, they included, analysed and followed up both lesions.  
Despite not being strictly ‘solitary’ pulmonary nodule studies these were included in the analysis as 
they reflect routine clinical practice where a second smaller nodule is identified when CT is 
performed following detection of a nodule on chest radiograph.  Some studies reported average 
follow-up of the nodules detected on CT, rather than a minimal follow-up period.  Cancellation of 
follow-up after resolution of the nodule in the case of infectious/inflammatory nodules would 
reduce the mean length of follow-up below the pre-stated 2 year minimum, yet nodules are 
considered benign if they resolve.  Therefore these studies were included in the meta-analysis.  They 
were however classed as being at high risk of bias with regards to their application of the reference 
standard on the QUADAS-2 questionnaire due to the uncertainty about the minimum length of 
follow-up in stable nodules.  The impact of this on the results was analysed as described below. 
Statistical analysis 
Numbers of true positives, false positives, true negatives and false negatives were extracted from 
the studies and used to form 2×2 contingency tables which were used to derive sensitivity, 
specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odds ratio 
(DOR).  Results were pooled using the lme4 package within R (RStudio Version 1.1.463, RStudio, Inc.) 
to perform a bivariate binomial random effects meta-analysis [16]. This uses a binary (logit) 
generalized linear mixed model fit by maximum likelihood (using a laplace approximation).   Bivariate 
summary receiver operator characteristic (SROC) curves were constructed using the bivariate 
random effects model outputs to populate the SROC plot within Review Manager Version 5.3. (The 
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Cochrane Collaboration).  To identify potential sources of heterogeneity, we stratified a secondary 
analysis into subgroups according to characteristics such as sample size, lesion size, risk of bias (low 
versus high/indeterminate), diagnostic thresholds, whether the diagnostic threshold was 
prospectively set and year of publication.  These were included as covariates, in turn, in a meta-
regression analysis, with analysis of statistical significance between models performed using a 
likelihood ratio test of nested models. For sample size, the threshold at which to split the data was 
arbitrarily set at 100 to represent larger samples that were less likely to be prone to bias due to 
outliers.  For mean nodule size the sample was split at 20mm to provide a reasonable split of the 
data.  For maximum nodule size the data was split based on whether the study included nodules 
>30mm, as the 30mm diameter is considered by most guidelines as the upper threshold for a lesion 
to be called a nodule, after which it is considered to be a mass.  Effect of publication date was 
examined by splitting on the median (2008), with studies published in the last decade considered to 
be more representative of modern CT technology. In studies reporting the diagnostic accuracy of 
multiple thresholds, the optimal threshold was used in the primary analysis.  In the secondary 
analyses examining different thresholds, studies were included in each sub group analysis where 
they had reported the threshold of interest. Thresholds with ≤2 studies reporting the same threshold 
were not considered for this secondary analysis.  To test for study publication bias and heterogeneity 
a Galbraith plot was created to examine the interaction between the efficient score and variance, 
with the Harbord test used to test for funnel plot asymmetry [17].   All statistical analysis was 
performed using RStudio.  Forest plots and SROC curves were generated using RevMan.    
 
RESULTS   
Of 3028 potential papers identified by the literature review, 22 were included which met the 
inclusion and exclusion criteria.  An additional study was located from the references of the included 
papers resulting in 23 studies in the final analysis.  Figure 1 details the flow of the studies identified, 
screened for eligibility, and the reasons for study exclusion. 
 
23 studies were included, incorporating the results from 2397 patients with 2514 nodules.  Of these 
1389/2514 (55.3%) were malignant.  The studies were predominantly retrospective single centre 
studies, performed in a wide range of countries and settings (Table 1).  The dynamic contrast 
enhanced CT protocol varied widely from study to study, from the injection rate to the scan timing 
to the tube settings (Table 2). 18 studies were performed using mono-energetic (routine) CT with 
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regular interval imaging, and 5 were performed using CT perfusion techniques.   The injection 
techniques included a standardised volume bolus and injection rate; adjusting the contrast volume 
to the weight of the patient; or adjusting the injection rate to the weight of the patient.  Image 
acquisition ranged from 3 volume acquisitions at different phases of the contrast injection to 32 
separate acquisitions. Most studies utilised an enhancement subtraction technique, taking the phase 
with the maximum nodule attenuation and subtracting the baseline attenuation to calculate the 
degree of enhancement.  However several studies utilised the slope of the enhancement curve or 
the area under the enhancement curve. 
 
The results of the QUADAS-2 bias and applicability assessment are summarised in Figure 2 whilst 
Table 3 documents the individual bias scores for the seven domains for all included studies.  Bias in 
patient selection was unclear in a large number (14/23, 61%) of studies due to a lack of reporting of 
the sampling of patients for the diagnostic test accuracy evaluation, with many retrospective studies 
not clearly documenting whether consecutive cases were included or not. Risk of bias in the index 
test was high in a large number of studies (12/23, 52%) due to a lack of pre-specification of the 
intended threshold to be used, and in several studies multiple techniques of enhancement of 
quantification were used simultaneously (including but not limited to absolute contrast 
enhancement, relative contrast enhancement, wash-in, wash-out, wash in and wash-out, and area 
under the enhancement curve).  Bias regarding the reference standard was unclear in the majority of 
studies (18/23, 78%), with the blinding of the reference standard to the index test infrequently 
reported.  Flow and timing had a similar high rate frequency of uncertainty bias (15/23, 65%), with 
the delay between the index test and reference standard infrequently reported.   Concerns 
regarding the applicability of the included studies to the review question were low for the majority 
of the studies (Figure 2).   
 
The results of the individual studies sensitivities and specificities are collated in a forest plot in Figure 
3, with all studies reporting a per nodule diagnostic accuracy. The pooled analysis of the 24 studies is 
reported in Table 4.  The pooled sensitivity and specificity were 94.8 (95% CI 91.5 ; 96.9) and 75.5 
(95% CI 69.4 ; 80.6) respectively (see SROC plot in Figure 4), with a positive and negative likelihood 
ratio of 3.86 (2.99 ; 4.74) and 0.07 (0.03 ; 0.10), and a diagnostic odds ratio of 56.6 (24.2 ; 88.9).  
Only two distinct enhancement thresholds were reported by >2 studies with the pooled analysis for 
each of these reported in Table 4.  Of these, a threshold of <20 Hounsfield units (HU) enhancement 
for the differentiation of a malignant from a benign nodule had the highest diagnostic odds ratio of 
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142.5 (95% CI -36.4 ; 321.3), maintaining a high sensitivity of 98.3% (95% CI 95.1 ; 99.4) and 
moderate specificity of 71.0% (95% CI 63.1 ; 77.8) (Table 4).   
 
The Galbraith plot (Figure 5) demonstrated multiple studies falling outwith the 95% confidence 
intervals consistent with a significant inter-study heterogeneity in findings, but there was not any 
significant asymmetry in the plot (p=0.90) to suggest publication bias. A formal analysis of the 
degree of heterogeneity was not performed as per the Cochrane Collaborations recommendations 
on diagnostic test accuracy meta-analysis; however factors that may have contributed to the 
heterogeneity were examined (Table 5).  Studies with a low risk for reference standard bias 
demonstrated a higher sensitivity and with equivalent specificity compared with studies with 
intermediate/high risk (p=0.044). However only two studies - both conducted by the same group - 
were considered to be at low risk.  Studies conducted pre-2008 had slightly higher sensitivity and 
specificity compared with those from 2008 onwards although this did not reach statistical 
significance (p=0.07). The CT technique (mono-energetic, versus perfusion) did not affect diagnostic 
accuracy (p=0.42). No difference was present between subgroups when studies were split based on 
sample size, mean or maximum nodule size, threshold prospectively or retrospectively set, or the 
presence of patient selection bias, index test bias or flow and timing bias (p>0.1 for all). In particular, 
there was no significant difference in the pooled sensitivity or specificity between studies that only 
included nodules ≤30mm (and therefore meet current definitions of SPNs) compared with those that 








DISCUSSION   
This meta-analysis demonstrates a high sensitivity and moderate specificity for dynamic contrast 
enhanced computed tomography for the diagnosis of solitary pulmonary nodules with a pooled 
sensitivity and specificity of 94.8% and 75.5% respectively.  However the study quality was 
indeterminate in a significant proportion of the studies with only one multi-centre study and a large 
number of small single centre studies. While the analysis shows promising results for the technique, 
the low quality of the included studies must be taken into account and further carefully designed 
high quality multi-centre studies are required. 
The current Fleischner guidelines for further investigation and management of indeterminate 
solitary pulmonary nodules call for either PET/CT or biopsy if the nodule is >8mm [6], with dynamic 
contrast enhanced computed tomography not mentioned in the diagnostic pathway despite 
inclusion of the technique in the 2005 version of the guidelines [5].  The British Thoracic Society 
guidelines state that dynamic contrast enhanced computed tomography should not be used where 
positron emission tomography is available although it is acknowledged that there is little evidence to 
support this beyond the historical prerogative of PET/CT [7].  A recent meta-analysis of PET/CT 
including 20 studies with 1,557 participants reported a sensitivity and specificity of 89% and 70%, 
and a diagnostic odds ratio (DOR) of 22 [39]. These results are similar to the DCE-CT results obtained 
in this meta-analysis with the 23 studies including 2397 participants, demonstrating a pooled 
sensitivity, specificity and DOR of 95%, 76% and 57 respectively.  This suggests that DCE-CT could 
replace PET/CT as an equivalent diagnostic technique.  Currently there are a limited number of 
studies directly comparing DCE-CT with PET/CT, precluding the ability to perform a meta-analytic 
comparison.  Ohno et al. compared DCE-CT with both PET/CT and dynamic contrast enhanced MRI in 
a single centre study of 198 patients, and found that DCE-CT out performed both MRI and PET/CT in 
specificity and accuracy [10].  This contradicted results of Yi et al. who found, in a single centre study 
of 119 participants, that PET/CT was more sensitive with equal specificity to that of DCE-CT [40].  
Thus further work is required to directly compare these two modalities.  Another technique that has 
a growing body of evidence is that of diffusion weighted MRI (DW-MRI).  While PET/CT examines 
metabolism and DCE-CT measures perfusion, DW-MRI quantifies the movement of water within the 
lesion.  A recent meta-analysis of diffusion-weighted MRI for the diagnosis of indeterminate solitary 
pulmonary nodules has suggested superiority of this technique compared to PET/CT with a pooled 
sensitivity, specificity and DOR of 83%, 91% and 50 respectively for diffusion weighted MRI 
compared with 78%, 81% and 15 for PET/CT [41]. Furthermore, dynamic contrast enhancement can 
also be quantified on MRI in the same examination as the assessment of diffusion [42]. Given the 
differing nature of the 3 parameters in question, further research is needed to determine whether 
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the information from perfusion, diffusion and metabolism are complimentary or duplicative in 
improving diagnostic accuracy. 
The equivalent sensitivity, specificity and accuracy in this meta-analysis of DCE-CT compared to 
previous meta-analysis of PET/CT provides supportive evidence for consideration of incorporation of 
DCE-CT into the diagnostic pathway of pulmonary nodules.  CT machines are more commonly found 
and more readily accessible in hospital settings than PET/CT.  A dynamic contrast examination is very 
similar to a standard contrast CT procedure which is commonly undertaken at all hospitals and 
requires no additional equipment. A PET/CT examination requires the injection of a radioactive 
substrate, which needs to be delivered reliably to centres undertaking PET examinations.  The 
requirement of such a supply chain can have significant impact on service flexibility and can result in 
scan cancellations when there is disruption or delay in delivery of the radioactive agent [43].  Future 
studies examining whether certain subgroups of pulmonary nodules (such as small size) or those 
found in patients with different risk profiles and likelihood of malignancy may have more to gain 
from a DCE-CT examination than PET/CT are also required.  Similarly a tiered approach using DCE-CT 
as the first diagnostic test and gatekeeper to PET/CT may allow for a more nuanced work-up 
approach utilising the strengths of both techniques.  Such an approach has been shown to be a cost 
effective approach to the diagnosis of SPNs [44]. Robust direct comparative accuracy of DCE-CT and 
PET/CT in the same population and cost effectiveness studies are warranted to test the various 
diagnostic pathways. 
There are several limitations with the current meta-analysis.  The quality of the included studies was 
frequently indeterminate due to lack of reporting of key metrics.  The studies were almost 
exclusively single centre and frequently retrospective, both of which are likely to amplify the 
apparent diagnostic accuracy of the technique.  In addition the dynamic contrast acquisition 
technique and the metrics for the quantification of the enhancement were heterogeneous 
throughout the studies.  Whilst these factors did not appear to have an impact on the accuracy of 
meta-regression, a standardised acquisition and analysis technique should be agreed upon to 
improve reproducibility and facilitate comparison between trials thereby allowing more widespread 
adoption. The observed rate of malignancy in the included studies is relatively high (55%). Whilst this 
is consistent with previous meta-analysis of MRI and PET in SPNs [39, 41], it is substantially higher 
when compared to screening detected SPNs such as in the National Lung Screening Trial (15.0% 
malignancy in 10-30mm nodules) and NELSON trial (15.2% malignancy in nodules >10mm) [45, 46].  
Previous work has shown the sensitivity of a technique to be relatively robust to disease prevalence 
and for the specificity to increase with falling prevalence [47]. It can be postulated that the 




In conclusion we have found a high diagnostic accuracy of DCE-CT for the diagnosis of pulmonary 
nodules although study quality was poor or indeterminate in a large number of cases.  The 
diagnostic accuracy is comparable to a recent meta-analysis of PET/CT suggesting that DCE-CT may 
compliment or augment the current diagnostic pathway used for the investigation of solitary 
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Table 1: Summary of the study design and baseline characteristics of those included in the meta-
analysis 
 
B = Benign; M = Malignant; FU = Follow-up 
* Value not provided for whole cohort and could not be calculated based on sub-group reported 
values. 
 
Table 2: Summary of the CT acquisition protocols and measurements of the studies included in the 
meta-analysis 
 
^ Scan type as follows: 1 – mono-energetic dynamic contrast enhanced computed 
tomography; 2 – computed tomography perfusion. 
& Hounsfield unit difference between baseline and peak enhancement unless otherwise 
stated 
 
Table 3: Table of the QUADAS-2 components for each of the individual studies 
☺Low Risk High Risk   ? Unclear Risk  
 
Table 4: Diagnostic performance of Dynamic contrast enhanced CT for the evaluation of 
pulmonary nodules. 
 
HU = Hounsfield units; NLR = Negative likelihood ratio; PLR = Positive likelihood ratio; DOR = 




Table 5: Subgroup Analyses of the Diagnostic Performance of DCE-CT for Evaluation of 
Indeterminate Pulmonary Lesions 
 
*Mean lesion size not reported in 3 studies, and reported as volumes rather than diameter in 3 
studies, max lesion size reported as volumes in 3 studies. 
CTP = Computer tomography perfusion; DECT = Dual energy dynamic contrast enhanced computer 





Figure 1: Flow diagram of the articles identified by the literature search, screened for eligibility, and 
included in the final study. 
 
CT = Computed tomography; MRI = Magnetic resonance imaging; PET/CT = Positron Emission 
Tomography; SPECT = Single positron emission computed tomography. 
 
Figure 2: QUADAS scoring summary of the included studies 
 
Figure 3: Forest plot of the included studies 
 
Studies listed by first author and year of publication 
CI = Confidence intervals; FN = False negative; FP = False positive; TN = True negative; TP = True 
positive 
 
Figure 4: Bivariate SROC curve of the included studies.  The white circles indicate each individual 
study whilst the black circle indicates the summary point.  The dotted line is the 95% confidence 
region for the summary operating point, whilst the dashed line is the 95% prediction region (which is 
the confidence region for a forecast of the true sensitivity and specificity in any future study). 
 
Figure 5: Galbraith plot examining inter-study heterogeneity for publication bias by incorporating 
the effect size of each study compared with the pooled analysis. The y-axis represents the test 
statistics (effect/standard error of the estimate) of each study, which are expected to fall within 2 
units of the pooled effects for 95% of the studies. The x-axis plots 1/standard error of the pooled 
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